3-Bromopyruvate as a potential pharmaceutical in the light of experimental data
Journal Title: Advances in Hygiene and Experimental Medicine - Year 2017, Vol 71, Issue
Abstract
3-Bromopyruvate (3-BrPA) is an halogenated analogue of pyruvic acid known for over four decades as an alkylating agent reacting with thiol groups of many proteins. It enters animal cells like a lactate: via monocarboxylic acid transporters. Increasing interest in this compound, in recent times, is mainly due to hopes associated with its anticancer action. It is based on the impairment of energy metabolism of tumor cells by inhibiting enzymes in the glycolysis pathway (hexokinase II, glyceraldehyde 3-phosphate dehydrogenase, phosphoglycerate kinase) and the oxidative phosphorylation (succinate dehydrogenase). Two cases of clinical application of this compound in the treatment of advanced cancers were reported. By using 3-BrPA, rheumatoid arthritis in SKG mice has been reduced. This compound has also antiparasitic activity: lowers cell viability of Trypanosoma brucei, decreases intracellular proliferation of Toxoplasma gondii and reduces the metabolic activity of Schistosoma mansoni. It also has antifungal properties; particularly it acts strongly on Cryptococcus neoformans, as well as Saccharomyces cerevisiae. An inhibitory effect on bacterial enzymes was also described on: isocitrate lyase from Escherichia coli, Mycobacterium tuberculosis, Pseudomonas indigofera and 2-methylisocitrate lyase, succinate dehydrogenase and acetohydroxylic acid synthase from Escherichia coli. Wherever undesirable (cancer, parasitic) cells differ from normal by more intense glycolysis and higher energy needs, there is a good chance of successful 3-BrPA use. However, this compound acts on all cells and it, therefore, seems that its future as a pharmaceutical is dependent upon the development of appropriate methods for its effective and safe application.
Authors and Affiliations
Izabela Szczuka, Andrzej Gamian, Grzegorz Terlecki
Keywords
Related Articles
- EP ID EP241431
- DOI 10.5604/01.3001.0010.6666
- Views 181
- Downloads 0
Carbon monoxide in human physiology – its role in the gastrointestinal tract
Carbon monoxide (CO) is produced endogenously in the body as a byproduct of heme degradation catalyzed by the action of heme oxygenase (HO) enzymes. An inducible form, HO-1, responds to many factors such as oxidative str...
Wpływ cytrynianu sodu na funkcję cewników naczyniowych używanych na potrzeby hemodializy oraz występowanie powikłań krwotocznych i infekcyjnych związanych z ich używaniem
Zapewnienie dostępu naczyniowego to jeden z najważniejszych problemów hemodializoterapii. Uważa się, iż najlepszym dostępem naczyniowym u chorych hemodializowanych jest przetoka tętniczo-żylna z naczyń własnych. Niestety...
A game of survival: herpesvirus strategies of autophagy manipulation
Viruses are a very “clever” group of pathogens and well known for disrupting multiple processes in host cells. One of them is autophagy, a conserved mechanism that relies on degradation of intracellular structures in lys...
Engineered spider silk: the intelligent biomaterial of the future. Part II
The development and progress in engineered spider silk manufacturing has enabled its practical application. Recombinant spider silk can assemble in several morphological forms such as films, hydrogels, fibers, scaffold...
Sclerostin and chronic kidney disease
Chronic kidney disease (CKD) leads to the development of mineral and skeletal disturbances. They increase the risk of fractures, cardiovascular complications and, in consequence, decrease patients’ lifespan. Wnt/β-cateni...